Get to know our clinical trials
Clinical trial of GEN3014 (HexaBody®-CD38) in relapsed or refractory multiple myeloma and other hematological malignancies.
THE PURPOSE OF THIS TRIAL IS TO INVESTIGATE THE SAFETY IT OFFERS IN PATIENTS WITH DIFFERENT TYPES OF BLOOD CANCERS AND TO FIND THE BEST DOSE TO TREAT THEIR DISEASE.
- PHASE I/II, MULTICENTER, UNBLINDED, UNBLINDED TRIAL OF GEN3014 (HEXABODY®-CD38) IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA AND OTHER HEMATOLOGIC MALIGNANCIES.
- Code EudraCT: 2020-003781-40
- Protocol number: GCT3014-01
- Promoter: Genmab A/S
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.